Natco Pharma Ltd
Natco Pharma Ltd (NATCOPHARM) last reported results for the quarter ended Jun 2026, with sales of ₹735 crore and net profit of ₹206 crore. The next scheduled event is a rights issue on 12 Oct 2026. The stock last traded at ₹821, a market capitalisation of ₹16,109 crore, on a P/E of 14.1. Over the past 52 weeks the stock has ranged between ₹786 and ₹1,217. Figures are as of 6 Oct 2026 and are not real time.
Natco Pharma Ltd share price and key metrics
- Current price
- ₹821
- Market cap
- ₹16,109 cr
- Stock P/E
- 14.1
- Book value
- ₹470
- ROE
- 17.1%
- ROCE
- 17.4%
- Dividend yield
- 0.61%
- 52w high / low
- 1217/786
Metrics as of 6 Oct 2026. Not real time.
Track Natco Pharma Ltd
Cruxal reads every Natco Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Natco Pharma Ltd growth and returns
- 10 Years
- 15%
- 5 Years
- 15%
- 3 Years
- 15%
- TTM
- -21%
- 10 Years
- 25%
- 5 Years
- 28%
- 3 Years
- 27%
- TTM
- -33%
- 10 Years
- 3%
- 5 Years
- -2%
- 3 Years
- -1%
- 1 Year
- 2%
- 10 Years
- 19%
- 5 Years
- 19%
- 3 Years
- 23%
- Last Year
- 17%
Natco Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹735 cr, down 44.7% from ₹1,329 cr a year earlier. Net profit was ₹206 cr, down 57.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 |
| Expenses | 567 | 436 | 673 | 758 | 784 | 489 | 612 | 549 |
| Operating profit | 804 | 39 | 548 | 571 | 579 | 159 | 128 | 186 |
| OPM % | 59% | 8% | 45% | 43% | 42% | 25% | 17% | 25% |
| Other income | 64 | 176 | 66 | 62 | 100 | 58 | 78 | 59 |
| Interest | 4 | 4 | 10 | 3 | 13 | 10 | 11 | 13 |
| Depreciation | 46 | 47 | 98 | 58 | 52 | 46 | 50 | 47 |
| Profit before tax | 818 | 164 | 506 | 572 | 614 | 161 | 144 | 186 |
| Tax % | 17% | 19% | 20% | 16% | 16% | 13% | -62% | 34% |
| Net profit | 676 | 132 | 406 | 480 | 518 | 151 | 269 | 206 |
| EPS (₹) | 34.52 | 6.78 | 20.72 | 24.50 | 26.42 | 7.72 | 13.65 | 10.52 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Natco Pharma Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,020 | 2,185 | 2,094 | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 | 4,430 | 4,078 | 3,485 |
| Operating profit | 683 | 928 | 795 | 583 | 606 | 264 | 936 | 1,754 | 2,196 | 1,462 | 1,052 |
| OPM % | 34% | 42% | 38% | 30% | 30% | 14% | 35% | 44% | 50% | 36% | 30% |
| Net profit | 485 | 695 | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,883 | 1,418 | 1,145 |
| EPS (₹) | 25.46 | 34.45 | 32.17 | 23.11 | 22.08 | 8.50 | 35.78 | 70.76 | 96.10 | 72.30 | 58.31 |
TTM is the trailing twelve months to the most recent quarter.
Natco Pharma Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 35 | 37 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 |
| Reserves | 1,614 | 3,035 | 3,452 | 3,737 | 4,085 | 4,227 | 4,837 | 5,817 | 7,571 | 9,185 |
| Borrowings | 222 | 173 | 386 | 316 | 268 | 416 | 167 | 371 | 279 | 714 |
| Other liabilities | 446 | 470 | 428 | 498 | 403 | 430 | 617 | 682 | 744 | 1,138 |
| Total liabilities | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 | 8,631 | 11,074 |
| Fixed assets | 833 | 1,019 | 1,227 | 1,584 | 2,023 | 2,312 | 2,427 | 2,491 | 2,698 | 2,803 |
| CWIP | 336 | 480 | 638 | 518 | 223 | 130 | 64 | 137 | 225 | 294 |
| Investments | 32 | 76 | 169 | 112 | 304 | 308 | 392 | 539 | 474 | 3,127 |
| Other assets | 1,116 | 2,140 | 2,270 | 2,373 | 2,242 | 2,360 | 2,774 | 3,739 | 5,234 | 4,850 |
| Total assets | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 | 8,631 | 11,074 |
As reported by the company. Total assets equal total liabilities by construction.
Natco Pharma Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 346 | 464 | 669 | 417 | 299 | 46 | 849 | 1,212 | 1,697 | 1,768 |
| Cash from investing | -299 | -1,116 | -611 | -175 | -107 | 4 | -465 | -1,026 | -1,436 | -1,987 |
| Cash from financing | -48 | 651 | -51 | -251 | -186 | 35 | -363 | -247 | -211 | 298 |
| Net cash flow | -1 | -2 | 7 | -8 | 6 | 85 | 21 | -62 | 50 | 79 |
| Free cash flow | 66 | 57 | 225 | 81 | 92 | -142 | 674 | 855 | 1,300 | 1,379 |
| CFO / operating profit | 69% | 72% | 107% | 90% | 71% | 36% | 110% | 85% | 94% | 148% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Natco Pharma Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 39% | 35% | 23% | 14% | 13% | 4% | 18% | 30% | 33% | 17% |
| Debtor days | 86 | 106 | 88 | 105 | 73 | 116 | 115 | 109 | 103 | 79 |
| Inventory days | 213 | 389 | 545 | 534 | 570 | 496 | 432 | 357 | 405 | 480 |
| Days payable | 160 | 239 | 224 | 244 | 104 | 105 | 153 | 120 | 145 | 216 |
| Cash conversion cycle | 138 | 257 | 410 | 395 | 539 | 507 | 394 | 345 | 362 | 343 |
| Working capital days | 71 | 215 | 207 | 295 | 246 | 256 | 198 | 151 | 151 | 111 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Natco Pharma Ltd shareholding pattern
Promoters held 49.41% at Jun 2026, broadly unchanged since Jun 2025. FIIs 16.99% and DIIs 5.63%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 49.62% | 49.62% | 49.56% | 49.56% | 49.48% | 49.48% | 49.41% | 49.41% |
| FIIs | 17.51% | 17.94% | 17.49% | 15.52% | 14.09% | 15.16% | 17.37% | 16.99% |
| DIIs | 6.75% | 5.59% | 5.64% | 5.81% | 5.87% | 5.39% | 5.46% | 5.63% |
| Public | 26.13% | 26.88% | 27.30% | 29.12% | 30.56% | 29.97% | 27.74% | 27.97% |
| No. of shareholders | 3,02,944 | 3,45,332 | 4,05,222 | 4,29,434 | 4,19,699 | 4,24,167 | 4,10,970 | 4,03,166 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Natco Pharma Ltd events
The next scheduled event is a rights issue on 12 Oct 2026.
- Rights issueRights issue of 1,70,58,082 equity shares at a price of ₹750 per share
See the full results calendar for every Indian company reporting in the next 30 days.
Natco Pharma Ltd corporate filings
- Natco Pharma publishes newspaper advertisement as part of routine compliance updateCompany Updatelow impact
Cruxal's analysis: On October 7, 2026, Natco Pharma Ltd released a newspaper publication related to…
Read the full analysis - Natco Pharma Limited reports strong Q2 FY2026 earnings with a 43% EPS beat, driven by robust revenue growth and margin expansionAGM/EGMhigh impact
Cruxal's analysis: Natco Pharma Limited has announced its quarterly results showing a significant EPS of INR…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- NATCO Pharma Limited's AGM Proceedings Confirm Key Business Continuity and Capital Raising PlansAGM/EGMhigh impact
Cruxal's analysis: NATCO Pharma Limited held its 43rd AGM on 30th September 2026 via video conference, with…
Read the full analysis - Natco Pharma Limited Announces Rights Issue of 1,279.4 crore INROthersmedium impact
Cruxal's analysis: Natco Pharma Limited has officially approved the Letter of Offer for a rights issue of up…
Read the full analysis - Natco Pharma Ltd: Disclosure under Regulation 30 of SEBI (LODR) RegulationsCompany Updatelow impact
Cruxal's analysis: Natco Pharma has issued a routine disclosure under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Natco Pharma Limited Announces Record Date for Rights IssueCompany Updatemedium impact
Cruxal's analysis: Natco Pharma Limited has officially fixed Thursday, 1 October 2026, as the Record Date to…
Read the full analysis - Natco Pharma Limited fixes October 1, 2026 as record date for upcoming Rights IssueCorp. Actionmedium impact
Cruxal's analysis: Natco Pharma Limited has officially announced Thursday, October 1, 2026, as the record…
Read the full analysis - Natco Pharma Announces INR 1,279.36 Crore Rights Issue at INR 750 Per ShareCompany Updatemedium impact
Cruxal's analysis: Natco Pharma Limited has approved a rights issue of 1.71 crore equity shares to raise INR…
Read the full analysis - Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on September 25, 2026, has decided to issue equity shares on rights basis in the ratio of 2 : ....Board Meetingmedium impact
- Natco Pharma Limited schedules board meeting on 25th September 2026 to finalize terms of 1,300 crore rights issueBoard Meetingmedium impact
Cruxal's analysis: Natco Pharma Limited has announced a board meeting scheduled for 25th September 2026 to…
Read the full analysis - Natco Pharma Limited Receives In-Principle Approval for Rights Issue from BSE and NSECompany Updatemedium impact
Cruxal's analysis: Natco Pharma Limited has secured in-principle approval from both the BSE and NSE for its…
Read the full analysis - Natco Pharma Ltd files Draft Letter of Offer for securities issuanceCompany Updatemedium impact
Cruxal's analysis: Natco Pharma has filed a Draft Letter of Offer under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Natco Pharma Announces Rights Issue of up to 1,300 crore and Updates Demerger SchemeBoard Meetingmedium impact
Cruxal's analysis: Natco Pharma Limited has approved a rights issue of equity shares for an amount not…
Read the full analysis - Natco Pharma Ltd: Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: Natco Pharma Ltd has fulfilled its regulatory obligation under Regulation 30 of the SEBI…
Read the full analysis - Natco Pharma Ltd schedules investor meetCompany Updatelow impact
Cruxal's analysis: Natco Pharma Ltd has issued an intimation regarding an upcoming analyst/investor meet…
Read the full analysis - Natco Pharma Limited: Promoter executes off-market gift of 50,000 equity sharesInsider Trading / SASTlow impact
Cruxal's analysis: Natco Pharma Limited has disclosed an off-market transfer of 50,000 equity shares by…
Read the full analysis - Natco Pharma announces strategic investment in eGenesis, Inc.Company Updatemedium impact
Cruxal's analysis: Natco Pharma has disclosed a strategic investment in eGenesis, Inc., a biotechnology…
Read the full analysis - Natco Pharma Ltd schedules investor meetCompany Updatelow impact
Cruxal's analysis: Natco Pharma has issued an intimation regarding an upcoming investor meet. The filing…
Read the full analysis - Natco Pharma concludes US FDA inspection at Visakhapatnam FDF unitCompany Updatelow impact
Cruxal's analysis: Natco Pharma has announced the conclusion of a US FDA inspection at its Finished Dosage…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.